Skip to main content

Table 2 Characteristics of studies involved in chemotherapy of PT treatment

From: Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis

Author Year Countr Follow-Up Chemo regime No. chemoth Surgery Type(%) Age Tumor Size (cm) Histological Type(%) Margin LR DFS OS MS
BCS M Be Bo M < 1 cm (%) (positive) > 1 cm (%) (negative)
Chaney, 2000 USA 47 m doxorubicin- ifosfamide ifosfamide 4300 mg 4 47 53 41(median) 4 / 20 80 (1) (99) 0 0 4 4
Guillot, 2011 France 12.65 m Adriamycin 100 mg *6 9 97 3 44(median) 3 / / 100 28 72 2 6 6 2
Morales 2007 Mexico 15 m Doxorubicin + dacarbazine 17 23.5 76.5 42(median) 13 / / 100 (24) (76) 6 / 14 10
Wang, F. 2014 China NA NA 8 61.4 38.6 49(mean) 5 / / 100 NA NA / 5 6 /
  1. Chemo-Chemotherapy; BCS breast conserving surgery, M mastectomy, Be benign, Bo borderline, LR local recurrence, DFS disease-free survival, OS overall survival, MS metastasis, NA not available